NCT05691153 - ThisCART19A for B-NHL Relapsed After Auto-CAR T | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

CARB Cell LymphomaRelapsed Non-Hodgkin Lymphoma

Interventions

DRUG

ThisCART19A with Dose Level 1

ThisCART19A，2×10\^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16

DRUG

ThisCART19A with Dose Level 2

ThisCART19A，3×10\^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16

Trial Locations (1)

215000

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou